355818-98-3

Usage

Uses

Used in Medicinal Chemistry:
6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE is used as a precursor in the synthesis of functionalized naphthyridines for their biological activities and pharmacological properties. The nitro group in the compound allows for further chemical modifications, leading to the development of new pharmaceuticals with potential therapeutic applications.
Used in Agrochemicals:
6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE is used as a starting material in the synthesis of agrochemicals, such as pesticides and herbicides. 6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE's unique structure and functional groups enable the development of novel agrochemicals with improved efficacy and selectivity.
Used in Organic Synthesis:
6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE is used as an intermediate in organic synthesis, particularly for the production of complex molecules. The BOC protecting group allows for selective reactions and subsequent deprotection steps, facilitating the synthesis of target molecules with desired properties.
Used in Research and Development:
6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE is used as a research compound in the study of naphthyridine derivatives and their potential applications. It serves as a valuable tool for understanding the structure-activity relationships and exploring new avenues for drug discovery and development.

Upstream product

• 14150-94-8 3,5-dinitro-1-methyl-2-pyridone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 785774-74-5 5,6,7,8-tetrahydro-1,6-naphthyridin-3-ol 
• 1184950-48-8 3-bromo-6-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 53454-30-1 3-Amino-1.6-naphthyridin 
• 123792-68-7 5,6,7,8-tetrahydro-3-nitro-1,6-naphthyridine 
• 355819-02-2 tert-butyl 3-amino-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carboxylate 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

RESORCINOL DERIVATIVE AS HSP90 INHIBITOR

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

An expeditious synthesis of 3-(difluoromethoxy)- and 3-(trifluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridines

An expeditious and concise synthesis of 3-(difluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine and 3-(trifluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridines is described. Starting from N-benzyl piperidone, the key intermediates leading to these two bio

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

SCH 58261 is a reported adenosine A2A receptor antagonist which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A1 receptor and does not demonstrate oral activity. Quinoline analogs have improved upon the selectivity and pharmacokinetics of SCH 58261, but were difficult to handle due to poor aqueous solubility. We report the design and synthesis of fused heterocyclic analogs of SCH 58261 with aqueous solubility as well as improved A2A receptor binding selectivity and pharmacokinetic properties. In particular, the tetrahydronaphthyridine 4s has excellent A2A receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 μM at physiological pH.

COMPOUNDS AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein R1, R2, Ra and Rb have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

A facile synthesis of the 3-amino-5,6,7,8-tetrahydro[1,6]naphthyridine system and some alkylated and polycyclic homologues

A facile, two step synthesis of the 3-amino-5,6,7,8-tetrahydro[1,6]naphthyridine system 1 and its more substituted homologues 2-5 via the condensation of mono- and bicyclic-4-piperidinones 11a-c, 12-14 with 3,5-dinitro-1-methyl-2-pyridone 6 in the presenc